Cell line · CVCL_1356
Papers43
1 to 20 of 43
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Suppression of AKT Activation through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP5 regulates purine metabolism and represents a therapeutic target in esophageal cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PDIA6 promotes the cell proliferation of ESCC by enhancing the disulfide bond formation in TRAF4. | Cell Mol Biol Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Patient-derived organoid xenografts model esophageal cancer cachexia and enable assessment of anti-inflammatory drug repositioning. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Probiotic-derived ferrichrome induces DDIT3-mediated antitumor effects in esophageal cancer cells. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Circulating long non-coding RNA EWSAT1 acts as a liquid biopsy marker for esophageal squamous cell carcinoma: A pilot study. | Noncoding RNA Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
Multigene Profiling of Circulating Tumor Cells in Esophageal Squamous Cell Carcinoma Identifies Prognostic Cancer Driver Genes Associated with Epithelial-Mesenchymal-Transition Progression and Chemoresistance. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting LncRNA LLNLR-299G3.1 with antisense oligonucleotide inhibits malignancy of esophageal squamous cell carcinoma cells in vitro and in vivo. | Oncol Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Integrative proteogenomic characterization of early esophageal cancer. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Effect of Opioid Receptor Activation and Blockage on the Progression and Response to Treatment of Head and Neck Squamous Cell Carcinoma. | J Clin Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma. | EBioMedicine | 2021 | Its Methods give the RRID and name the line | PubMed | |
| A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. | Neoplasia | 2021 | Its Methods give the RRID and name the line | PubMed | |
| MicroRNA-146a suppresses tumor malignancy via targeting vimentin in esophageal squamous cell carcinoma cells with lower fibronectin membrane assembly. | J Biomed Sci | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1356/papers